title: Clinical evaluation of the safety and efficacy of 10% imidacloprid + 2.5% moxidectin topical solution for the treatment of ear mite (Otodectes cynotis) infestations in dogs.
abstract: A clinical field investigation was conducted to evaluate the safety and efficacy of 10% imidacloprid/2.5% moxidectin for the treatment of ear mites (Otodectes cynotis) in dogs. The study was a multi-centered, blinded, positive controlled, randomized clinical trial conducted under field conditions with privately owned pets. A total of 17 veterinary clinics enrolled cases for the study. An otoscopic examination was performed to confirm the presence of O. cynotis residing in the ear of the dog prior to enrollment. A single-dog household was enrolled in the study if the dog had 5 or more ear mites and an acceptable physical examination. A multi-dog household was eligible if at least one dog in the household had 5 or more mites and all dogs in the household had acceptable physical exams and met the inclusion criteria. Qualified households were randomly assigned to treatments to receive either 10% imidacloprid+2.5% moxidectin topical solution or topical selamectin solution (positive control product) according to a pre-designated enrollment ratio of 2:1, respectively. If more than one dog in a multiple dog household had adequate numbers of ear mites, one dog was randomly selected to represent the household for efficacy evaluation prior to treatment. Treatments were administered twice per label and dose banding directions for each product approximately 28 days apart (Days 0 and 28), by the dog's owner at the study site. All dogs in a household were treated on the same day and with the same product. The owners completed a post-treatment observation form one day after each treatment. Post-treatment otoscopic examinations were performed by the investigators or attending veterinarian on Days 28 and 56. Physical examinations were performed on Days 0 and 56. One hundred and four (104) households were evaluated for efficacy on SD 28, and 102 households were evaluated for efficacy on SD 56. The dogs' ages ranged from 2 months to 16 years. A total of 247 dogs were evaluated for safety. Percent efficacy was based on the percentage of dogs cleared of ear mites. Mite clearance on Day 28 was 71% for the imidacloprid+moxidectin group and 69% for the selamectin group. Mite clearance on Day 56 was 82% for the imidacloprid+moxidectin group and 74% for the selamectin group. No serious adverse events associated with either product were observed during the study. The study demonstrated that 10% imidacloprid+2.5% moxidectin applied using two topical treatments, 28 days apart, was safe and achieved similar efficacy against O. cynotis as selamectin treatments applied and evaluated under the same conditions.
authors: Clinical Development, Bayer HealthCare, Animal Health Division, Shawnee, KS, United States. Electronic address: bob.arther@bayer.com.
authors: R G
authors: RG
authors: Arther
authors: Clinical Development, Bayer HealthCare, Animal Health Division, Shawnee, KS, United States.
authors: W L
authors: WL
authors: Davis
authors: AlcheraBio LLC, Edison, NJ, United States.
authors: J A
authors: JA
authors: Jacobsen
authors: AlcheraBio LLC, Edison, NJ, United States.
authors: V A
authors: VA
authors: Lewis
authors: Clinical Development, Bayer HealthCare, Animal Health Division, Shawnee, KS, United States.
authors: T L
authors: TL
authors: Settje
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy / Q000469:parasitology*; D004285:Dogs; D004338:Drug Combinations; D004427:Ear Diseases / Q000469:parasitology / Q000662:veterinary*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007306:Insecticides / Q000008:administration & dosage / Q000627:therapeutic use; D007559:Ivermectin / Q000031:analogs & derivatives / Q000627:therapeutic use; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008924:Mite Infestations / Q000662:veterinary*; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D007093:Imidazoles; D007306:Insecticides; D018942:Macrolides; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; D007559:Ivermectin; C414354:selamectin; C027837:moxidectin
keywords: Dogs; Ear mites; Imidacloprid/moxidectin; Otodectes; Selamectin